Journal: International Journal of Molecular Sciences

Article Title: Human Antibody Domains and Fragments Targeting Neutrophil Elastase as Candidate Therapeutics for Cancer and Inflammation-Related Diseases

doi: 10.3390/ijms222011136

Figure Lengend Snippet: Epitope mapping of V H -Fc 1D1.43 and IgG1 1C10 by using conformational epitope mappings. ( a ) Competition between V H -Fc 1D1.43 and IgG1 1C10 measured by BLItz. ( b ) The binding region of V H 1D1.43 and Fab 1C10 on hNE (PDB: 3Q76) based on the conformational epitope mapping results with the binding motifs highlighted by dot presentations. The enzymatic sites are shown by the stick models. ( c , d ) The detailed binding model of Fab 1C10 and V H 1D1.43 on hNE, as predicted by Z-DOCK programs. Human NE is represented as green cartoons with active site highlighted by sticks and binding epitope highlighted by blue color. Fab 1C10 and V H 1D1.43 are represented as cyan cartoons with highlighted colored CDR loops.

Article Snippet: Conformational epitope mapping was proceeded by PEPperPRINT GmbH (Heidelberg, Germany).

Techniques: Binding Assay

Journal: mAbs

Article Title: T and B cell epitope analysis for the immunogenicity evaluation and mitigation of antibody-based therapeutics

doi: 10.1080/19420862.2024.2324836

Figure Lengend Snippet: The summary and comparison of various strategies applied for pBCEs identification.

Article Snippet: A recent proof-of-concept work by Genentech involves FPOP-based ADA epitope mapping of a clinical candidate bispecific antibody.

Techniques: Comparison

Journal: mAbs

Article Title: TTAC-0001, a human monoclonal antibody targeting VEGFR-2/KDR, blocks tumor angiogenesis

doi: 10.1080/19420862.2015.1045168

Figure Lengend Snippet: Domain and epitope mapping of anti-KDR antibodies. (a) Domain mapping analysis of anti-KDR antibodies on the extracellular region of KDR. Black bar represents extracellular domain 1 and 2 of KDR (KDR (ECD 1–2)). Gray bar represents extracellular domain 2 and 3 of KDR (KDR (ECD 2–3)). White bar represents extracellular domain 1, 2 and 3 of KDR (KDR (ECD 1–3)). (b) Peptide microarray for epitope mapping. As an antigen, KDR (ECD1–3) was used. The sequence was scanned with a format of 13meric peptides overlapping 11 amino acid residues with the following peptide, resulting in a total of 149 peptides. The binding of primary antibody (TTAC-0001, control human IgG) to the peptide was measured with dylight-649 labeled secondary antibody. Left panel: Fluorescence intensity of peptide. The intensity of fluorescence measured by TTAC-0001 was subtracted the value of control human IgG (Pierce). Arrows indicate peptides showing over 10,000 LU of signal intensity. Right panel: Amino acid sequence (peptide i.d.) showed high intensity of fluorescence (≥ 10,000 LU). The sequences inside the box indicate epitopes for TTAC-0001.

Article Snippet: Peptide microarray of epitope mapping Peptide microarray for epitope mapping was done by Abnova (Taipei city, Taiwan).

Techniques: Peptide Microarray, Sequencing, Binding Assay, Control, Labeling, Fluorescence